Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027

Appili adopts a new business strategy that focuses on the biodefence sector

Halifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless otherwise stated.